Skip to main content
TipRanks
Go Ultimate75% OFF

Linical Co., Ltd. (2183) AI Stock Analysis

1 Followers
JP:2183

Linical Co., Ltd.

(TSE/TYO:2183)

Select Model
Rating:41Neutral
Price Target:JPY 188.00â–¼(-3.09% Downside)
Action:reiterated
Date:11/18/26

Linical scores poorly, driven primarily by a sharply deteriorating financial profile: three consecutive years of revenue decline, collapsed gross margins, a projected ¥3.3 billion net loss, negative EBITDA, and negative operating and free cash flow that is rapidly eroding an already halved equity base. Technicals reinforce the caution, with the stock trading below all major moving averages and a negative MACD, though a low Stochastic reading hints at near-term oversold conditions. Valuation provides little support — earnings are negative, and the 4.06% dividend yield is not covered by current cash generation, raising sustainability risk. Modest positives include some debt reduction, still-positive equity, and low beta. Earnings call and corporate event components were excluded due to missing data, with their weight redistributed across the remaining factors.

Positive Factors
Contracted CRO ServicesLinical operates in an established outsourced-services model, helping pharmaceutical and biotechnology customers execute clinical development. Contract-based fees tied to work performed provide a repeatable commercial framework, while project complexity and duration can support sustained demand when the company wins and retains sponsor work.
Negative Factors
Revenue and Profitability DeclineThe latest results show a material weakening in earnings power rather than a minor fluctuation: revenue contracted, gross margin fell to about 9%, and operating and net margins became deeply negative. If the decline persists, lower utilization and weaker operating leverage could pressure results across the next several quarters.

Linical Co., Ltd. (2183) vs. iShares MSCI Japan ETF (EWJ)

-40%-30%-20%-10%0%10%20%30%JP:2183-33.56%EWJ+11.78%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 4.34B
Dividend Yield
4.12%
Average Volume (3M)
52.63K
Price to Earnings (P/E)
-1.2
Beta (1Y)
0.58
Revenue Growth
-23.55%
EPS Growth
-205.65%
Country
Japan
Employees
577
Sector
Healthcare
Sector Strength
51
Industry
Specialty Business Services

Linical Co., Ltd. Business Overview & Revenue Model

Company Description

Linical Co., Ltd., a global contract research organization provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in deve...

How the Company Makes Money

Linical makes money primarily by selling outsourced clinical development services to pharmaceutical, biotechnology, and related life-science customers. Revenue is generally earned under service contracts where Linical is paid fees for executing defin...

Linical Co., Ltd. Financial Statement Overview

Summary

Financials are in severe distress. Revenue has fallen for three straight years (-31% cumulatively, -14.5% most recently), gross margins have collapsed from ~33% to ~8.7%, and the company is projected to post a ¥3.3 billion net loss (-38.4% net margin) with negative EBITDA. Operating cash flow has swung from +¥1.9 billion to -¥1.5 billion, with free cash flow at -¥1.6 billion, meaning the business is now consuming reserves. The balance sheet offers only a thin cushion: equity has been halved to ¥4.0 billion, debt-to-equity has risen to 0.57, and ROE is -83.7%. Modest offsets include some deleveraging (total debt down to ¥2.3 billion) and still-positive equity, but the trajectory points to possible dilution or restructuring without a turnaround.

Income Statement

15Very Negative

Balance Sheet

30Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue7.95B8.67B10.44B12.31B12.52B11.56B
Gross Profit119.13M753.13M2.01B3.43B3.84B3.34B
EBITDA-2.21B-1.54B-46.50M1.25B1.76B1.54B
Net Income-3.79B-3.33B-539.10M338.27M1.00B790.49M
Balance Sheet
Total Assets11.06B12.00B16.78B18.54B17.46B15.72B
Cash, Cash Equivalents and Short-Term Investments4.68B5.20B7.04B7.47B7.04B5.99B
Total Debt2.04B2.25B2.42B3.00B3.63B4.19B
Total Liabilities7.85B8.02B9.52B10.30B9.88B9.17B
Stockholders Equity3.21B3.98B7.25B8.24B7.58B6.54B
Cash Flow
Free Cash Flow0-1.55B602.21M1.08B1.85B1.64B
Operating Cash Flow0-1.52B605.10M1.11B1.86B1.68B
Investing Cash Flow0-1.96M-54.93M-70.47M-31.79M-32.14M
Financing Cash Flow0-513.25M-939.22M-960.92M-957.33M-951.55M

Linical Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price194.00

Price Trends

50DMA200.90Negative
100DMA204.27Negative
200DMA232.89Negative

Market Momentum

MACD-1.92Positive
RSI38.55Neutral
STOCH49.40Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2183, the sentiment is Negative. The current price of 194.00 is below the 20-day moving average (MA) of 197.55, below the 50-day MA of 200.90, and below the 200-day MA of 232.89, indicating a bearish trend. The MACD of -1.92 indicates Positive momentum. The RSI at 38.55 is Neutral, neither overbought nor oversold. The STOCH value of 49.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2183.

Linical Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:2183 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4891JP:489156NeutralJPY 6.54B-5.90――――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4978JP:497845NeutralJPY 11.75B-24.37――-8.23%-48.10%
JP:2342JP:234244NeutralJPY 3.02B-156.08――8.53%97.93%
JP:2183JP:218341NeutralJPY 4.38B-1.20―4.12%-23.55%-205.65%
JP:2370JP:237038UnderperformJPY 4.55B-2.95――1.41%1.12%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%JP:2183JP:2342JP:2370JP:4891JP:4978Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:2183 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:2183Linical Co., Ltd.194.00-97.98-33.56%
JP:2342Trans Genic Inc.179.00-31.00-14.76%
JP:2370MEDINET Co., Ltd.16.00-17.00-51.52%
JP:4891TMS Co., Ltd.135.00-2.00-1.46%
JP:4978ReproCELL Inc.110.00-51.00-31.68%

Linical Co., Ltd. Corporate Events

Linical Reports Six-Month Sales Decline and Larger Losses

Nov 16, 2026

Linical Co., Ltd., listed on the Tokyo Stock Exchange, reported consolidated net sales of ¥3,739 million for the six months ended September 30, 2026, down 23.0% year on year. Operating loss was ¥1,280 million, ordinary loss was ¥1,360 million, and lo...

Linical Wins $20 Million U.S. Biotech Order as FDA Environment Normalizes

Oct 9, 2026

Linical Co., Ltd. has secured a large new order from a U.S. biotechnology company worth 20.4 million dollars, or 3,212 million yen, reinforcing its role as a key clinical development partner in the global life sciences market. The mandate follows a p...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026